Home
About
About The Guide to IMMUNOPHARMACOLOGY
The Guide to PHARMACOLOGY
About The Guide to PHARMACOLOGY
About NC-IUPHAR
Contributors
Sponsors
Citing
Linking to us
Disclaimer
Privacy and Cookie Policy
Targets
GPCRs
Ion channels
LGICs
VGICs
Other channels
Nuclear receptors
Kinases
Catalytic receptors
Transporters
Enzymes
Other protein targets
Target search
Target search tools
BLAST
Ligands
Ligand list
Ligand families
Ligand search
Processes
Antigen presentation
Barrier integrity
B cell (activation)
Cellular signalling
Chemotaxis & migration
Cytokine production & signalling
Immune regulation
Immune system development
Inflammation
T cell (activation)
Tissue repair
Cell Types
B-cells
Dendritic cells
Granulocytes
Innate lymphoid cells
Macrophages/monocytes
Mast cells
Natural killer (NK) cells
T-cells (alpha/beta)
Other T-cells (NKT, MAIT, TRM etc.)
Stromal cells
Diseases
Resources
GtoImmuPdb Further Reading
GtoImmuPdb Help & Downloads
GtoImmuPdb Tutorial
Useful Links
Immunopharmacology Meeting 2018
GtoPdb Help
FAQ
Terms and symbols
Nomenclature guidelines
Publications
Drug approvals
Concise Guide to PHARMACOLOGY
Useful links
GtoPdb Downloads
Download data and reports
Web services
Slides and posters
GtoPdb News
Latest GtoPdb news
Hot topics
Guide to PHARMACOLOGY
Home
About
Help
Home
Ligands
atibuclimab
atibuclimab
GtoPdb Ligand ID: 11326
Synonyms:
IC14
Compound class:
Antibody
Comment:
Atibuclimab (IC14) is a monoclonal antibody against CD14 [
1
]. It was developed by ICOS Corporation (acquired by Eli Lilly) and was progressed as a potential COVID-19 therapeutic by Implicit Bioscience.
Summary
Biological activity
Clinical data
References
Immunopharmacology
Selectivity at other protein targets
Key to terms and symbols
Click column headers to sort
Target
Sp.
Type
Action
Value
Parameter
Concentration range (M)
Reference
CD14 molecule
Hs
Antibody
Binding
-
-
-
1
,
5
⤷
[
1
,
5
]